Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating alemtuzumab in pediatric relapsing-remitting multiple sclerosis with disease activity on prior disease-modifying therapy was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2022-07-12